Affiliation:
1. Noida Institute of Engineering & Technology (Pharmacy Institute) 19, Knowledge Park – II, Institutional Area Greater Noida – 201306, Uttar Pradesh, India.
2. Noida Institute of Engineering & Technology (Pharmacy Institute) 19, Knowledge Park – II, Institutional Area Greater Noida – 201306, Uttar Pradesh, India
Abstract
Metformin is a biguanide that has been used extensively worldwide for the treatment of type II diabetes mellitus. It improves glycaemic control by enhancing insulin sensitivity in liver and muscle. An advantage of metformin treatment is the tendency of weight reduction and the absence of significant hypoglycaemia; blood glucose levels are reduced only to normal as it does not stimulate insulin secretion. Metformin also has a beneficial effect on several cardiovascular risk factors including dyslipidemia, elevated plasminogen activator inhibitor 1 levels, other fibrinolytic abnormalities, hyperinsulinemia, and insulin resistance. Metformin enhances muscle and adipocyte insulin receptor number and/or affinity, increases insulin receptor tyrosine kinase activity, stimulates glucose transport and glycogen synthesis, and reduces both hepatic gluconeogenesis and glycogenolysis. The disadvantages are confined to the gastro-intestinal side effects and the potential risk of vitamin B 12 and folic acid deficiency during long-term use. These side effects can be minimized by slow titration and consumption with meals. The under lying mechanism for gastrointestinal intolerance are proposed to be stimulation of intestinal secretion of serotonin, alteration in incretin and metabolism of glucose, and malabsorption of bile salts. Lactic acidosis is rare contraindication associated with metformin. Most reported cases of lactic acidosis occur in patients with contraindications, particularly impaired renal function. Metformin has a good safety profile, efficacy and comparatively reduced cost. Its ability to improve insulin sensitivity and the cardiovascular risk profile of type II diabetic patients has enhanced its clinical use as first-line therapy.
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference112 articles.
1. Norris SL, Engelgau MM, Narayan KM., Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care, 2001; 24: 561-587
2. Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK. Robbins and Cotran Pathologic basis of disease. Philadelphia, Saunders, 2005; 7: 1156-1226.
3. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nature reviews endocrinology. Available at: www.nature.com/uidfinder (Accessed 1st April 2020)
4. Genetic basis of type 1and type 2 diabetes, obesity, and their complications. Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC. www2.niddk.nih.gov/NR (Accessed 1st April 2020).
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010;33(1):11‑61.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献